Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Interventions: Drug: Pegaspargase
Drug: Erwinia asparaginase
Drug: Cyclophosphamide
Drug: DEXAMETHASONE
Drug: CYTARABINE
Drug: DASATINIB
Drug: LEUCOVORIN CALCIUM
Drug: Dexrazoxane
Drug: Doxorubicin
Drug: MERCAPTOPURINE
Drug: METHOTREXATE
Drug: ETOPOSIDE
Drug: HYDROCORTISONE
Drug: Vincristine
Drug: NELARABINE

First Posted Date: 2017-01-13

Last Posted Date: 2025-01-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 560

Registration Number: NCT03020030

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦
Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada

and more 6 locations

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Lenalidomide
Drug: Melphalan
Biological: Rituximab

First Posted Date: 2017-01-12

Last Posted Date: 2023-02-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03019640

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Phase 2

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2017-01-11

Last Posted Date: 2017-01-11

Lead Sponsor: Tingbo Liu

Target Recruit Count: 50

Registration Number: NCT03016988

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Phase 2

Completed

Conditions: Acute Leukemia of Ambiguous Lineage
Myeloid Neoplasm
Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Granulocyte Colony-Stimulating Factor
Drug: Mitoxantrone Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-01-06

Last Posted Date: 2022-03-08

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT03012672

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia

Interventions: Drug: Calaspargase Pegol
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Dexrazoxane Hydrochloride
Drug: Doxorubicin
Drug: Leucovorin Calcium
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Drug: Imatinib Mesylate
Drug: Methotrexate
Other: Laboratory Biomarker Analysis
Drug: Pegaspargase
Drug: Prednisolone
Drug: Mercaptopurine
Drug: Methylprednisolone
Other: Questionnaire Administration
Drug: Thioguanine
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2017-01-02

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 475

Registration Number: NCT03007147

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 224 locations

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Phase 3

Conditions: Acute Myeloid Leukemia, Adult

Interventions: Drug: Decitabine
Drug: Cytarabine

First Posted Date: 2016-12-07

Last Posted Date: 2016-12-07

Lead Sponsor: Chunyan Ji

Target Recruit Count: 30

Registration Number: NCT02985372

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Phase 1

Terminated

Conditions: Follicular Lymphoma Grade III (FL III°)
Mantle Cell Lymphoma (MCL), Blastoid Variant
Aggressive Marginal Zone Lymphoma (MZL)
Diffuse Large B-cell Lymphoma (DLBCL)
Burkitt Lymphoma (BL)

Interventions: Drug: Rituximab
Drug: Cisplatin
Drug: Carboplatin
Drug: Dexamethasone
Drug: Cytarabine
Drug: Lenalidomide
Drug: PegFilgrastim
Procedure: peripheral stem cell collection

First Posted Date: 2016-12-06

Last Posted Date: 2018-01-19

Lead Sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Target Recruit Count: 34

Registration Number: NCT02983097

Locations: 🇩🇪
LMU Klinikum München-Großhadern, München, Germany
🇩🇪
Diakonie Krankenhaus Bremen, Bremen, Germany
🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany

and more 9 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Recurrent B Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma

Interventions: Drug: Asparaginase Erwinia chrysanthemi
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Calaspargase Pegol
Drug: Cyclophosphamide
Drug: Cytarabine
Procedure: Diagnostic Imaging
Biological: Inotuzumab Ozogamicin
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Methotrexate
Drug: Pegaspargase
Drug: Vincristine

First Posted Date: 2016-12-05

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 80

Registration Number: NCT02981628

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-11-23

Last Posted Date: 2024-05-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 40

Registration Number: NCT02971397

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia, Relapsed, Adult

Interventions: Drug: F16IL2
Drug: cytarabine

First Posted Date: 2016-11-06

Last Posted Date: 2023-10-10

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 30

Registration Number: NCT02957032

Locations: 🇩🇪
Münster University Hospital, Münster, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy